- Home
- IHT vs CANF Comparison
IHT vs CANF Comparison
Compare IHT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHT | CANF |
|---|---|---|
| Founded | 1971 | 1994 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 6.7M |
| IPO Year | 1995 | 2011 |
Fundamental Metrics
Financial Performance| Metric | IHT | CANF |
|---|---|---|
| Price | $1.34 | $2.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 21.9K | ★ 180.7K |
| Earning Date | 05-12-2026 | 03-26-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $7,600,000.00 | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $0.17 |
| 52 Week High | $4.24 | $10.40 |
Technical Indicators
Market Signals| Indicator | IHT | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 27.53 |
| Support Level | $1.23 | $0.17 |
| Resistance Level | $1.51 | $3.59 |
| Average True Range (ATR) | 0.10 | 0.14 |
| MACD | 0.00 | -0.13 |
| Stochastic Oscillator | 37.18 | 1.54 |
Price Performance
Historical ComparisonAbout IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.